Epicrispr Biotechnologies, Inc.

BiotechnologyBiotechnologyEpigeneticsGene Modulation

📍 SOUTH SAN FRANCISCO, CA• Founded 2022

StreetZero Signal 71

Be the first to signal interest

About Epicrispr Biotechnologies, Inc.

Epicrispr Biotechnologies is a biotechnology company pioneering programmable epigenetic medicines using its proprietary Gene Expression Modulation System (GEMS) platform. Founded by CRISPR pioneer Stanley Qi, the company develops ultracompact therapies to modulate gene expression in vivo, with a lead program EPI-321 in clinical trials for facioscapulohumeral muscular dystrophy (FSHD) and additional programs targeting neuromuscular and other diseases. It holds an exclusive license to the smallest known Cas protein and focuses on first-in-class treatments for previously untreatable conditions. The company is headquartered in South San Francisco, California, and launched in July 2022.

LATEST FUNDINGPrivate Placement

$176.8M

Announced 2026-08-26

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Epicrispr Biotechnologies, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2022

HQSOUTH SAN FRANCISCO, CA

Industry

Biotechnology

Investors

Octagon Capital Janus Henderson Investors Fidelity Management & Research Company Cormorant Asset Management Duquesne Family Office Sanofi Ventures abrdn Inc.Angelini Ventures Readout Capital

Key highlights

Launched in July 2022 with $55 million Series A led by its CRISPR founder technology.
Secured $68 million Series B in March 2025 to initiate clinical trials for EPI-321 in FSHD.
Closed $90 million Series C in August 2026 co-led by Octagon Capital and Janus Henderson Investors.
Named a Fierce 15 company by Fierce Biotech for its GEMS platform advances.
Lead program EPI-321 targets facioscapulohumeral muscular dystrophy with additional preclinical programs in A1AD and HeFH.